Pseudomyxoma peritonei (PMP) is a rare and highly heterogeneous clinicopathological syndrome, characterized primarily by the dissemination and implantation of mucin-secreting tumor cells within the abdominal cavity, along with the progressive accumulation of mucinous ascites. It most commonly arises as a complication of appendiceal mucinous tumors. In its early stages, the disease often progresses insidiously, typically presenting with abdominal distension and pain as initial clinical manifestations. Currently, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is considered the standard treatment for PMP. However, this therapeutic approach is associated with considerable surgical trauma and a high risk of postoperative complications. In the treatment of PMP, the central challenge lies in attaining effective CRS while simultaneously minimizing the risk of surgical complications.